UNSPSC 51343816: Lamivudine/tenofovir DF

This classification denotes a combination drug for treatment of HIV. The first component, LAMIVUDINE, has US FDA Unique Ingredient Identifier of 2T8Q726O95. The second component, TENOFOVIR DISOPROXIL FUMARATE, has US FDA Unique Ingredient Identifier of OTT9J7900I.

UNSPSC 51343816 Lamivudine/tenofovir DF is a Commodity code representing antiretroviral pharmaceutical products for HIV treatment. State and local procurement activity under this code is minimal; the recent opportunities block contains no solicitations for this specific medication or drug combination. The one pharmaceutical-related opportunity tagged to this code—Seminole County's June 2026 procurement of naloxone and drug deactivation systems—addresses opioid overdose response, not antiretroviral therapy, indicating a significant mismatch between the code's nominal scope and actual recent buying patterns in state and local markets.

The source does not support sufficient activity to characterize issuing-body mix, geographic concentration, or representative recent opportunities for lamivudine/tenofovir DF procurement. State and local governments appear to source this medication through existing health department contracts, pharmacy benefits programs, or Medicaid managed-care networks rather than through standalone competitive solicitations tagged to this commodity code. Vendors pursuing this market should focus on established relationships with state health agencies, county health departments, and managed-care entities rather than monitoring UNSPSC 51343816 opportunities, as the code does not surface meaningful state and local buying signals for this antiretroviral product.